Product Information
YUPELRI 175 MCG/3 ML SOLUTION is a brand product labeled by Viatris Specialty LLC, priced at $17.4271 per ML under NDC 49502080693. Its NADAC has been published 363 times since Oct 23, 2019.
FDA first approved this application on Nov 9, 2018.
Strength
175 ug/3mL
Manufacturer
Viatris Specialty LLCNDC
49502080693
Classification
Brand
Dosage Form
SOLUTION
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
REVEFENACINApproval Type
New Drug (NDA)
FDA Application
NDA210598FDA Approved
11/9/2018
On Market Since
12/3/2018
Pharmacological Classes
Price Statistics
The NADAC for YUPELRI 175 MCG/3 ML SOLUTION has been published 363 times since Oct 23, 2019, and over the history we have for it it has risen 59.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.4271 per ML |
|---|---|
| All-time high | $17.4859 (May 13, 2026) |
| All-time low | $10.9503 (Oct 23, 2019) |
| 52-week high | $17.4859 |
| 52-week low | $16.5979 |
| Median price | $13.7879 |
| Average price | $13.9790 |
| Largest weekly change | +9.9% (Jul 10, 2024) |
| Weeks tracked | 363 |
| Tracking since | Oct 23, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the revefenacin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viatris Specialty LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
revefenacin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of YUPELRI 175 MCG/3 ML SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for YUPELRI 175 MCG/3 ML SOLUTION, manufactured by Viatris Specialty LLC, is $17.4271 per ML (NDC 49502080693), effective Sep 30, 2026.
How has the price of YUPELRI 175 MCG/3 ML SOLUTION changed over time?
Over the history we have for it, the NADAC for YUPELRI 175 MCG/3 ML SOLUTION has risen 59.1%. It has been tracked across 363 weekly CMS publications since Oct 23, 2019.
What are the highest and lowest recorded NADAC prices for YUPELRI 175 MCG/3 ML SOLUTION?
Since Oct 23, 2019, the NADAC for YUPELRI 175 MCG/3 ML SOLUTION has ranged from a low of $10.9503 (Oct 23, 2019) to a high of $17.4859 (May 13, 2026), with a median of $13.7879 per ML.
Are there cheaper alternatives to YUPELRI 175 MCG/3 ML SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of YUPELRI 175 MCG/3 ML SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures YUPELRI 175 MCG/3 ML SOLUTION?
YUPELRI 175 MCG/3 ML SOLUTION (NDC 49502080693) is labeled by Viatris Specialty LLC, and CMS classifies it as a brand product.